Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2013





Summary 

Global Markets Direct’s, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer. Human papillomavirus (HPV) Associated Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. 

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

 

- A snapshot of the global therapeutic scenario for Human papillomavirus (HPV) Associated Cancer. 

- A review of the Human papillomavirus (HPV) Associated Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Human papillomavirus (HPV) Associated Cancer pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

 

Reasons to buy 

 

- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer. 

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Human papillomavirus (HPV) Associated Cancer Overview 8

Therapeutics Development 9

An Overview of Pipeline Products for Human papillomavirus (HPV) Associated Cancer 9

Human papillomavirus (HPV) Associated Cancer Therapeutics under Development by Companies 11

Human papillomavirus (HPV) Associated Cancer Therapeutics under Investigation by Universities/Institutes 13

Late Stage Products 14

Comparative Analysis 14

Mid Clinical Stage Products 15

Comparative Analysis 15

Early Clinical Stage Products 16

Comparative Analysis 16

Discovery and Pre-Clinical Stage Products 17

Comparative Analysis 17

Human papillomavirus (HPV) Associated Cancer Therapeutics – Products under Development by Companies 18

Human papillomavirus (HPV) Associated Cancer Therapeutics – Products under Investigation by Universities/Institutes 19

Companies Involved in Human papillomavirus (HPV) Associated Cancer Therapeutics Development 20

Merck & Co., Inc. 20

Transgene SA 21

Prima BioMed Limited 22

Antigen Express, Inc. 23

PDS Biotechnology Corporation 24

Etubics Corporation 25

iBio, Inc. 26

Sirnaomics, Inc. 27

Cancer Therapeutics CRC Pty Ltd 28

EyeGene, Inc. 29

Vaccibody AS 30

Coridon Pty Ltd 31

Human papillomavirus (HPV) Associated Cancer – Therapeutics Assessment 32

Assessment by Monotherapy Products 32

Assessment by Combination Products 33

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

PDS-0101 - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

V-503 - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

TG-4001 - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

HPV Vaccine - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

RBT-201 - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

HPV-Head and Neck Cancer Vaccine - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AEH-10p - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

P16_37-63 Vaccine - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

EG-HPV - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Human Papillomavirus Vaccine - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

STP-911 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Drug Targeting E6AP - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

HPV-16 E6 Peptides + Candin - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

HPV Vaccine - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

VB-1016 - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Anti-E6 Protein Antibodies - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Human papillomavirus (HPV) Associated Cancer Therapeutics – Drug Profile Updates 55

Human papillomavirus (HPV) Associated Cancer Therapeutics - Dormant Products 58

Human papillomavirus (HPV) Associated Cancer – Product Development Milestones 59

Featured News & Press Releases 59

Sep 04, 2012: Republic Of Uganda And Merck Launch Cervical Cancer Vaccination Program With Gardasil 59

Feb 28, 2012: Coridon To Develop New HPV Therapeutic Vaccine 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 62

Disclaimer 62

 

 

 

List of Tables

 

Number of Products Under Development for Human papillomavirus (HPV) Associated Cancer, H1 2013 9

Products under Development for Human papillomavirus (HPV) Associated Cancer – Comparative Analysis, H1 2013 10

Number of Products under Development by Companies, H1 2013 12

Number of Products under Investigation by Universities/Institutes, H1 2013 13

Comparative Analysis by Late Stage Development, H1 2013 14

Comparative Analysis by Mid Clinical Stage Development, H1 2013 15

Comparative Analysis by Early Clinical Stage Development, H1 2013 16

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17

Products under Development by Companies, H1 2013 18

Products under Investigation by Universities/Institutes, H1 2013 19

Merck & Co., Inc., H1 2013 20

Transgene SA, H1 2013 21

Prima BioMed Limited, H1 2013 22

Antigen Express, Inc., H1 2013 23

PDS Biotechnology Corporation, H1 2013 24

Etubics Corporation, H1 2013 25

iBio, Inc., H1 2013 26

Sirnaomics, Inc., H1 2013 27

Cancer Therapeutics CRC Pty Ltd, H1 2013 28

EyeGene, Inc., H1 2013 29

Vaccibody AS, H1 2013 30

Coridon Pty Ltd, H1 2013 31

Assessment by Monotherapy Products, H1 2013 32

Assessment by Combination Products, H1 2013 33

Assessment by Stage and Route of Administration, H1 2013 35

Assessment by Stage and Molecule Type, H1 2013 37

Human papillomavirus (HPV) Associated Cancer Therapeutics – Drug Profile Updates 55

Human papillomavirus (HPV) Associated Cancer Therapeutics – Dormant Products 58

 

 

 

List of Figures

 

Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2013 9

Products under Development for Human papillomavirus (HPV) Associated Cancer – Comparative Analysis, H1 2013 10

Products under Development by Companies, H1 2013 11

Products under Investigation by Universities/Institutes, H1 2013 13

Late Stage Products, H1 2013 14

Mid Clinical Stage Products, H1 2013 15

Early Clinical Stage Products, H1 2013 16

Discovery and Pre-Clinical Stage Products, H1 2013 17

Assessment by Monotherapy Products, H1 2013 32

Assessment by Combination Products, H1 2013 33

Assessment by Route of Administration, H1 2013 34

Assessment by Stage and Route of Administration, H1 2013 35

Assessment by Molecule Type, H1 2013 36

Assessment by Stage and Molecule Type, H1 2013 37